These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32659961)

  • 1. Correlation of MET and PD-L1 Expression in Malignant Melanoma.
    Song KY; Desar S; Pengo T; Shanley R; Giubellino A
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32659961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
    Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
    Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
    Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
    J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
    Thierauf J; Veit JA; Affolter A; Bergmann C; Grünow J; Laban S; Lennerz JK; Grünmüller L; Mauch C; Plinkert PK; Hess J; Hoffmann TK
    Melanoma Res; 2015 Dec; 25(6):503-9. PubMed ID: 26352784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
    Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
    Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression.
    Natali PG; Nicotra MR; Di Renzo MF; Prat M; Bigotti A; Cavaliere R; Comoglio PM
    Br J Cancer; 1993 Oct; 68(4):746-50. PubMed ID: 8104462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
    Shui IM; Liu XQ; Zhao Q; Kim ST; Sun Y; Yearley JH; Choudhury T; Webber AL; Krepler C; Cristescu R; Lee J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas.
    Wang HY; Wu XY; Zhang X; Yang XH; Long YK; Feng YF; Wang F
    Oncologist; 2020 Feb; 25(2):e291-e301. PubMed ID: 32043781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
    Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
    Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
    Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.
    Pinczewski J; Obeng RC; Slingluff CL; Engelhard VH
    Pathol Res Pract; 2021 Aug; 224():153527. PubMed ID: 34167064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
    Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
    Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
    Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
    Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
    Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
    [No Abstract]   [Full Text] [Related]  

  • 19. MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
    Reis H; Metzenmacher M; Goetz M; Savvidou N; Darwiche K; Aigner C; Herold T; Eberhardt WE; Skiba C; Hense J; Virchow I; Westerwick D; Bogner S; Ting S; Kasper S; Stuschke M; Nensa F; Herrmann K; Hager T; Schmid KW; Schuler M; Wiesweg M
    Clin Lung Cancer; 2018 Jul; 19(4):e441-e463. PubMed ID: 29631966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACC1 and MET as markers associated with progression and metastasis in cutaneous melanoma.
    Zhou Y; Rasner CJ; Giubellino A
    Front Oncol; 2023; 13():1146092. PubMed ID: 37496665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.